Ann: Investor Presentation , page-13

"TAD will manage the regulatory approval for the AutoStart Infusion System in the ensuing months and will undergo trials at local hospitals as part of the market entry process"

So we have regulatory approval first, then hospital trials and sales.

They mentioned at the presentation the regulatory approval is moving much faster than expected. Potential for sales before the end of this year.

Also said that the Brazil regulatory approval is also moving very quickly whilst they negotiate the final terms of the distribution agreement. Again, potential for sales before the end of the year.

Securing Brazil will be a big milestone for them.